| [1] |
JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling.
Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
|
| [2] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
| [3] |
MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe.
Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32.
|
| [4] |
WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan.
Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.
|
| [5] |
JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang.
Evaluation index system of MAH pharmacovigilance work
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
|
| [6] |
LIU Hongliang, WANG Qing, HOU Yongfang.
Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098.
|
| [7] |
LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing.
Management of individual adverse drug reaction reports
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
|
| [8] |
SHEN Yanjie, WU Yiqing.
Management of adverse events during clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
|
| [9] |
LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue.
Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
|
| [10] |
ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan.
Comparison standard terminology for pharmaceutical dose forms
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
|
| [11] |
ZHAO Xuan, GUO Jing, CHEN Ning, MEI Long, ZHENG Tingting, ZHANG Lifang, ZHANG Wei.
Discuss the safety management of medical toxic drugs in medical institutions
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 705-708.
|
| [12] |
SHA Mingquan, ZHANG Yawei, ZHOU Hongjie, WEN Baoshu.
A comparative progress and prospect for drug technological guidances system in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1045-1049.
|
| [13] |
SONG Mingyue, ZHANG Ran, WU Zhiang.
Influencing factors of quality risk management of drug recall in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1087-1090.
|
| [14] |
GENG Kexin, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, SA Rina, JIANG Hao, ZOU Lina.
Safety of traditional Chinese medicine among lactating women and pharmacovigilance
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 908-912.
|
| [15] |
ZHANG Qingxia, JIANG Yongxian, DONG Yuexin, XIAN Ying, YAN Suying.
Risk analysis and precautions related to storage conditions specified in package inserts of western medicines in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 913-918.
|
